A Phase 3 interventional study of Denosumab (CP2) and Denosumab (CP4) in Postmenopausal Osteoporosis, sponsored by Amgen. Completed at 23 sites in 4 countries. Open to female participants aged 55 Years to 100 Years. Per ClinicalTrials.gov, last updated 2017-08-16.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 12th largest by enrollment, is one of 3 that started in 2014, is one of 17 in phase 3, and was the 17th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 394 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
24 studies in Osteoporosis, Postmenopausal by Amgen: none open now, none under way, none of them phase 3. Of 24 finished, 23 (96%) have results posted.
Among the 24 studies in Osteoporosis, Postmenopausal by Amgen, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2014, is one of 14 in phase 3, and was the 20th registered.
Amgen’s Osteoporosis, Postmenopausal studies by the year they started, since 2004.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 24 in Osteoporosis, Postmenopausal:
This tab as a report to print or save as PDF → With an account.
This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 60 mg denosumab manufactured using the current CP2 process subcutaneously once every 6 months for 1 year.
Drug: Denosumab (CP2)
Participants received 60 mg denosumab manufactured using the new CP4 process subcutaneously once every 6 months for 1 year.
Drug: Denosumab (CP4)
Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
Also known as: XGEVA®
Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
Percent Change From Baseline in Lumbar Spine BMD
Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
Time frame: Baseline and Month 12
Percent Change From Baseline in Serum Type I Collagen C-telopeptide (sCTX)
Time frame: Baseline, month 1, month 6 and month 12
Percent Change From Baseline in Serum Procollagen Type 1 N-terminal Propeptide (P1NP)
Time frame: Baseline, month 1, month 6 and month 12
This study was conducted at 21 centers in Poland, Denmark, United States (US), and Canada. The first participant enrolled on 05 May 2014 and the last participant enrolled on 03 July 2014.
| Milestone | Denosumab CP2 | Denosumab CP4 |
|---|---|---|
| Started | 197 | 197 |
| Received treatment | 196 | 196 |
| Completed | 188 | 188 |
| Not completed | 9 | 9 |
| Withdrew: Withdrawal by subject | 4 | 5 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Protocol specified criteria | 2 | 1 |
| Withdrew: Decision by sponsor | 0 | 1 |
Lumbar spine bone mineral density (BMD) was measured by dual x-ray absorptiometry (DXA). DXA scans were analyzed by a central imaging center.
| percent change | Denosumab CP2 | Denosumab CP4 |
|---|---|---|
| Percent Change From Baseline in Lumbar Spine BMD | 5.78 ± 3.44 | 5.73 ± 3.08 |
| percent change | Denosumab CP2 | Denosumab CP4 |
|---|---|---|
| Month 1 (n = 195, 193) | -86.39 (-90.65 to -78.45) | -88.05 (-91.12 to -80.79) |
| Month 6 (n = 191, 189) | -76.46 (-85.58 to -60.58) | -79.48 (-87.06 to -66.86) |
| Month 12 (n = 187, 188) | -71.34 (-83.33 to -47.13) | -75.44 (-85.88 to -61.90) |
| percent change | Denosumab CP2 | Denosumab CP4 |
|---|---|---|
| Month 1 (n = 195, 193) | -29.59 (-38.06 to -20.02) | -29.86 (-38.80 to -20.90) |
| Month 6 (n = 192, 190) | -76.63 (-82.90 to -66.69) | -77.74 (-85.02 to -70.31) |
| Month 12 (n = 186, 188) | -71.44 (-77.64 to -57.35) | -72.08 (-80.24 to -62.40) |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab CP2 | — | 13/196 (6.6%) | 25/196 (12.8%) |
| Denosumab CP4 | — | 6/196 (3.1%) | 36/196 (18.4%) |
| Event | Denosumab CP2 | Denosumab CP4 |
|---|---|---|
| Carotid artery stenosisNervous system disorders | 2/196 | 0/196 |
| Ischaemic strokeNervous system disorders | 2/196 | 0/196 |
| AnaemiaBlood and lymphatic system disorders | 1/196 | 0/196 |
| ArrhythmiaCardiac disorders | 1/196 | 0/196 |
| VertigoEar and labyrinth disorders | 1/196 | 0/196 |
| GoitreEndocrine disorders | 1/196 | 0/196 |
| Abdominal painGastrointestinal disorders | 1/196 | 0/196 |
| AppendicitisInfections and infestations | 0/196 | 1/196 |
| DiverticulitisInfections and infestations | 1/196 | 1/196 |
| Femur fractureInjury, poisoning and procedural complications | 1/196 | 0/196 |
| Event | Denosumab CP2 | Denosumab CP4 |
|---|---|---|
| NasopharyngitisInfections and infestations | 15/196 | 21/196 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/196 | 15/196 |
| Age, Continuous(years) | Denosumab CP2 | Denosumab CP4 | Total |
|---|---|---|---|
| Mean | 68.0 ± 6.8 | 68.3 ± 7.3 | 68.1 ± 7.0 |
| Age, Customized(participants) | Denosumab CP2 | Denosumab CP4 | Total |
|---|---|---|---|
| < 65 years | 65 | 70 | 135 |
| ≥ 65 years | 132 | 127 | 259 |
| Sex: Female, Male(Participants) | Denosumab CP2 | Denosumab CP4 | Total |
|---|---|---|---|
| Female | 197 | 197 | 394 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Denosumab CP2 | Denosumab CP4 | Total |
|---|---|---|---|
| White | 190 | 195 | 385 |
| Asian | 4 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 2 | 1 | 3 |
| Other | 1 | 0 | 1 |
| Lumbar Spine Bone Mineral Density (BMD) Score(T-score) | Denosumab CP2 | Denosumab CP4 | Total |
|---|---|---|---|
| Mean | -2.75 ± 0.91 | -2.75 ± 0.75 | -2.75 ± 0.83 |
| Serum Type I Collagen C-telopeptide (CTX-1)(ng/mL) | Denosumab CP2 | Denosumab CP4 | Total |
|---|---|---|---|
| Median | 0.433 (0.268 to 0.610) | 0.462 (0.328 to 0.641) | 0.452 (0.295 to 0.618) |
| Serum Procollagen Type 1 N-terminal Propeptide (P1NP)(μg/L) | Denosumab CP2 | Denosumab CP4 | Total |
|---|---|---|---|
| Median | 56.6 (45.7 to 73.4) | 61.5 (45.1 to 75.6) | 59.3 (45.4 to 75.0) |
The record gives a start of May 2014, a primary completion of Jul 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2017, 2 years 1 month after primary completion. A results delay was requested in Nov 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →